TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03589170

Intervention type: DIAGNOSTIC_TEST
Intervention: Opportunistic atrial fibrillation screening
Description: Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
Study: NCT04256122

Intervention type: OTHER
Intervention: No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.
Description: evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.

Intervention type: OTHER
Intervention: No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.
Description: evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
Study: NCT02617355

Intervention type: DEVICE
Group type: OTHER
Intervention: DeRoyal Magnetic Pad size 20 x 16
Description: Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax

Intervention type: DEVICE
Group type: OTHER
Intervention: DeRoyal Magnetic Pad size 10 x 16
Description: Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax
Study: NCT02598882

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: videogame
Description: Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill
Description: Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
Study: NCT01249222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: plasmapheresis
Description: plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
Study: NCT01330186

Intervention type: OTHER
Intervention: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
Description: This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
Study: NCT03128905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine opocalcium 1mg
Description: International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone.
Study: NCT02150694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography
Description: Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography
Description: Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
Study: NCT01667263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Study: NCT02150694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aellig hand vein technique
Description: Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aellig hand vein technique
Description: Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin agonist infusion
Description: Escalating doses of apelin (1/10/100nmol/min) will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin agonist infusion
Description: Escalating doses of apelin (1/10/100nmol/min) will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin receptor antagonist infusion
Description: Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apelin receptor antagonist infusion
Description: Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
Study: NCT00523263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heparin-bonded and collagen coated polyster
Description: femoro-popliteal bypass
Study: NCT03128905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone : Cortancyl 20mg
Description: International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate.
Study: NCT03518905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: esophagoscopy
Description: Patients receive an esophagoscopy without radiofrequency ablation under sedation
Study: NCT03726866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: D326, D337 or CKD-828 for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: D326, D337 or CKD-828 for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3
Description: D326, D337 or CKD-828 for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: D326, D337 or CKD-828 for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: D326, D337 or CKD-828 for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: D326, D337 or CKD-828 for 9 days
Study: NCT04349917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A matching placebo pill will be administered on the placebo day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo pill will be administered on the placebo day.
Study: NCT03116659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg PO BID x 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: up to 2 packs 3/ week x 28 days
Study: NCT03584139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRIS HOOK
Description: iris hook assisted maneuver in phacoemulsification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRADITION
Description: traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
Study: NCT04008498

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AEEG brain monitoring
Description: Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.
Study: NCT03557762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
Study: NCT01930227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-acupoint stimulation
Description: Electric stimulation was given through electrode attached to the shoulder
Study: NCT02696694

Intervention type: OTHER
Intervention: Progesterone 25-75
Description: Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy

Intervention type: OTHER
Intervention: Progesterone <25, >75
Description: Impact of serum progesterone concentrations (\<25, \>75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
Study: NCT00641394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy: Emotional Freedom Techniques (EFT)
Description: A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
Study: NCT03025945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study: NCT00857935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse - 1%
Description: NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIX Creme Rinse - 1% permethrin
Description: NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
Study: NCT01159860

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryosurgery
Description: freezing of lesion with liquid nitrogen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: the lesion will be anesthetized and destroyed with a curette.
Study: NCT02087514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks
Study: NCT01667263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Study: NCT02087514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks
Study: NCT01956786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-FA tablet,low dose group
Description: 5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-FA tablet,high dose group
Description: 5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg amlodipine,once daily
Study: NCT01590420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP S8- Scape / Resmed
Description: The pressure for treatment is according to PSG titration
Study: NCT00899483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose potassium insulin solution
Description: Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
Study: NCT02925247

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence to oral anticoagulant treatment
Description: The adherence will be evaluated by biological results
Study: NCT02388191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Description: 550 mg, oral, on day 1. Number of Cycles: 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study: NCT03824119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Standard postpartum care (including administration of NSAIDs)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Postpartum Care without NSAIDs
Description: NSAID administration will be withheld from this group.
Study: NCT01433718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Resistance Training
Description: 1 hour/session, 3 sessions/week, 6 weeks
Study: NCT02350647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture Anchor HEALOCOIL
Description: Rotator cuff tears will be repaired intraoperatively using suture anchors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor Twinfix Ultra HA
Study: NCT02356302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicriviroc (MK-4176) Intravaginal Ring (IVR)
Description: Contains 182 mg vicriviroc (MK-4176).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MK-2048 IVR
Description: Contains 30 mg MK-2048.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR
Description: Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Study: NCT01873586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Fusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterolateral Fusion
Study: NCT02173418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phrenic nerve block with Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phrenic nerve block with saline
Study: NCT01108094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: * Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: * Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months
Study: NCT01954394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT01312415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.

Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal morphine
Description: Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
Study: NCT03970421

Intervention type: OTHER
Intervention: Observation
Description: Check clinical status at different time intervals during 3 months

Intervention type: OTHER
Intervention: Observation
Description: Check clinical status at different time intervals during 3 months

Intervention type: OTHER
Intervention: Observation
Description: Check clinical status at different time intervals during 3 months

Intervention type: OTHER
Intervention: Observation
Description: Check clinical status at different time intervals during 3 months
Study: NCT00523263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Human umbilical vein femoro-popliteal bypass
Study: NCT02610504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane
Description: single injection of 3ml
Study: NCT03219710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
Study: NCT03851250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx-4DP0004
Description: Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to receive placebo will take it in addition to their regular asthma medication.
Study: NCT01140581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRONEDARONE
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg